1. Distribution of anti‐factor Xa activity in patients with nonvalvular atrial fibrillation receiving 15 mg dose of edoxaban.
- Author
-
Hiramatsu, Shotaro, Osanai, Hiroyuki, Sakai, Yuichiro, Sogo, Yoshiki, Tanaka, Yuki, Matsumoto, Hikari, Miyamoto, Shun, Tagahara, Kensuke, Arai, Kenji, Watanabe, Takashi, Sakamoto, Yusuke, Sakaguchi, Teruhiro, Oguchi, Shioh, Kanbara, Takahiro, Nakashima, Yoshihito, Asano, Hiroshi, and Ajioka, Masayoshi
- Subjects
ANTICOAGULANTS ,LOW-molecular-weight heparin ,T-test (Statistics) ,SCIENTIFIC observation ,PROTHROMBIN time ,DESCRIPTIVE statistics ,MANN Whitney U Test ,CHI-squared test ,ORAL drug administration ,BLOOD coagulation factors ,ENOXAPARIN ,ATRIAL fibrillation ,COMPARATIVE studies ,STROKE - Abstract
Background: The distribution of anti‐factor Xa activity (AXA) in patients with nonvalvular atrial fibrillation (NVAF) taking edoxaban 15 mg has not been fully elucidated. Methods and Results: The trough and peak AXA were measured in 19 NVAF patients taking edoxaban 15 mg. We compared these results with those in patients taking edoxaban 30 mg. The peak AXA differed significantly between the 15 mg and the 30 mg groups (0.74 ± 0.40 IU/mL vs. 1.25 ± 0.48 IU/mL, respectively; p < 0.0001). Conclusions: Peak but trough AXA in the patients receiving edoxaban 15 mg were significantly lower than those in patients receiving edoxaban 30 mg. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF